New phocoenamicin and maklamicin analogues from cultures of three marine-derived Micromonospora strains
Kokkini, M.; Oves-Costales, D.; Sanchez, P.; Melguizo, A.; Mackenzie, T.A.; Perez-Bonilla, M.; Martin, J.; Giusti, A.; de Witte, P.; Vicente, F.; Genilloud, O.; Reyes, F. (2023). New phocoenamicin and maklamicin analogues from cultures of three marine-derived Micromonospora strains. Mar. Drugs 21(8): 443. https://dx.doi.org/10.3390/md21080443
In: Marine Drugs. Molecular Diversity Preservation International (MDPI): Basel. ISSN 1660-3397; e-ISSN 1660-3397, more
|   |
| Keywords |
Micromonospora Orskov, 1923 [WoRMS]
Marine/Coastal |
| Author keywords |
antimicrobial resistance; drug discovery; natural products; marine actinomycetes; polyketides; spirotetronates; phocoenamicins |
| Authors | | Top |
- Kokkini, M.
- Oves-Costales, D.
- Sanchez, P.
- Melguizo, A.
|
- Mackenzie, T.A.
- Perez-Bonilla, M.
- Martin, J.
- Giusti, A., more
|
- de Witte, P., more
- Vicente, F.
- Genilloud, O.
- Reyes, F.
|
| Abstract |
Antimicrobial resistance can be considered a hidden global pandemic and research must be reinforced for the discovery of new antibiotics. The spirotetronate class of polyketides, with more than 100 bioactive compounds described to date, has recently grown with the discovery of phocoenamicins, compounds displaying different antibiotic activities. Three marine Micromonospora strains (CA-214671, CA-214658 and CA-218877), identified as phocoenamicins producers, were chosen to scale up their production and LC/HRMS analyses proved that EtOAc extracts from their culture broths produce several structurally related compounds not disclosed before. Herein, we report the production, isolation and structural elucidation of two new phocoenamicins, phocoenamicins D and E (1–2), along with the known phocoenamicin, phocoenamicins B and C (3–5), as well as maklamicin (7) and maklamicin B (6), the latter being reported for the first time as a natural product. All the isolated compounds were tested against various human pathogens and revealed diverse strong to negligible activity against methicillin-resistant Staphylococcus aureus, Mycobacterium tuberculosis H37Ra, Enterococcus faecium and Enterococcus faecalis. Their cell viability was also evaluated against the human liver adenocarcinoma cell line (Hep G2), demonstrating weak or no cytotoxicity. Lastly, the safety of the major compounds obtained, phocoenamicin (3), phocoenamicin B (4) and maklamicin (7), was tested against zebrafish eleuthero embryos and all of them displayed no toxicity up to a concentration of 25 μM.
|
|
